ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.
iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference:
Date: Tuesday, September 26, 2023
Time: 12:00 PM EDT
Event: Company presentation
Virtual viewers: https://www.webcaster4.com/Webcast/Page/2992/49116
For more information regarding the conference and to register to watch the presentation live, please visit the conference page here.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$16.54 |
| Daily Change: | -0.36 -2.13 |
| Daily Volume: | 120,469 |
| Market Cap: | US$108.340M |
January 07, 2025 November 13, 2024 September 10, 2024 August 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
